Hepatic xanthoma is an extremely rare lesion worldwide. We herein present a case of hepatic xanthoma that developed in a 27-year-old Taiwanese man who had participated in a clinical trial of pasireotide. This is, to the best of our knowledge, the first case of pasireotide-induced hepatic xanthoma. Following discontinuation of the drug, the tumor continued to decrease in size (98.2% decrease in tumor volume). We suggest that, in patients receiving pasireotide, the liver should be checked using periodic radiological examinations, even if the patient does not exhibit any risk factors, and that medical or surgical intervention may not be needed.